Return to homepagePandemic Pact

Developing an in vitro platform to screen therapeutic agents

  • Funded by UK Research and Innovation (UKRI)
  • Total publications:0 publications

Grant number: C19-IUC-085

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    UK Research and Innovation (UKRI)

  • Principal Investigator

    Ludovic Vallier

  • Research Location

    United Kingdom

  • Lead Research Institution

    Wellcome - Medical Research Council Cambridge Stem Cell Institute

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Developing an in vitro platform to screen therapeutic agents by exploring the hypothesis that infection of cholangiocytes (which express ACE2 receptor) may mediate hepatic dysfunction associated with virus infection. Developing an in vitro platform using primary cholangiocytes as organoids to screen therapeutic agents for their capacity to inhibit viral entry and study the mechanisms by which SARS-COV2 enter cells.